Permanent arteriovenous fistula or catheter dialysis for heart failure patients

• Published in: The journal of vascular access Vol. 17 Suppl 1; p. S23
• Main Author: Roca-Tey, Ramon
• Format: Journal Article
• Language: English
• Published: United States 01.03.2016
• Subjects: Arteriovenous Shunt, Surgical - adverse effects; Arteriovenous Shunt, Surgical - mortality; Catheterization, Central Venous - adverse effects; Catheterization, Central Venous - instrumentation; Catheterization, Central Venous - mortality; Catheters, Indwelling; Central Venous Catheters; Heart Failure - complications; Heart Failure - mortality; Heart Failure - physiopathology; Hemodynamics; Humans; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - mortality; Kidney Failure, Chronic - physiopathology; Kidney Failure, Chronic - therapy; Regional Blood Flow; Renal Dialysis - adverse effects; Renal Dialysis - mortality; Risk Factors; Treatment Outcome
• ISSN: 1724-6032
• DOI: 10.5301/jva.5000511

Heart failure (HF) is the most frequent cardiovascular disease associated with chronic kidney disease and represents a high risk for cardiovascular mortality in incident hemodialysis (HD) patients. This risk is especially high during the arteriovenous fistula (AVF) maturation period due to the marked hemodynamic changes related to the large increase in the blood flow and also within the first 120 days after HD inception because in this period the highest mortality rate occurs. When planning the vascular access for each incident HF patient, the risk of aggravating HF after AVF creation must be evaluated carefully alongside the risk of catheter-related complications, but avoiding a non-selective 'catheter first' approach for all these patients. HF patients classified within the New York Heart Association (NYHA) Class I-II and the American College of Cardiology/American Heart Association (ACC/AHA) Stage A-B could initiate HD through a distal arm AVF. High-flow brachial artery-based AVF creation must be avoided because it displays the highest risk of worsening the cardiac function. The decision for AVF creation or tunneled central catheter placement in HF patients classified within the NYHA Class III and the ACC/AHA Stage C must have been individualized according the degree of systolic and/or diastolic dysfunction. HF patients with significant reduction in systolic function (ejection fraction lower than 30%) or classified within the NYHA Class IV and the ACC/AHA Stage D, are candidates for tunneled catheter placement to start HD treatment.